Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Sanofi said it had discontinued the phase 3 URSA trial of tolebrutinib in patients with moderate-to-severe myasthenia gravis, but stressed the decision was taken for commercial reasons in light of ...

Dr. Pushpa, I want to start with you. What are the current treatment options when someone is newly diagnosed with myasthenia gravis? These are really exciting times, I think, for patients with ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) inhibitors, offer a new treatment paradigm ...

In June 2023, the Dutch biotech Argenx (ARGX) won FDA approval for its subcutaneously delivered myasthenia gravis therapy, Vyvgart Hytrulo, developed with Halozyme Therapeutics (HALO).

The Ministry of Food and Drug Safety announced on the 20th that it has approved the severe myasthenia gravis treatment "Vyvgart" (active ingredient efgartigimod alpha) from Belgian pharmaceutical ...